Safety and efficacy of edoxaban in patients undergoing hip fracture surgery

This report has been verified by one or more authors of the original publication.

92 patients undergoing hip fracture surgery were randomized to receive postoperative thromboprophylaxis with either oral once-daily edoxaban or once- or twice-daily subcutaneous injections of enoxaparin. This study aimed to compare the safety and efficacy between these two anticoagulant therapies. Results indicated a comparable percentage of patients with a major or clinically relevant non-major bleeding event between groups, while minor bleeding events were higher in edoxaban patients. The proportion of patients with an adverse event was similar, as was the incidence of composite thromboembolic events.